(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Thursday revealed the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026.
Most recently, Snellgrove was with Johnson & Johnson leading investor relations. He brings more than 30 years experience.
Snellgrove will be responsible for leading Halozyme's financial operations and strategy, including capital allocation, corporate development and investor relations.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.